1
|
Godel-Pastre S, Porcel E, Pinna G, Vandamme M, Denis C, Leterrier C, Doris E, Truillet C, Gravel E. Tumor-Targeted Perfluorinated Micelles as Efficient Theranostic Agents Combining Positron Emission Tomography and Radiosensitization. ACS APPLIED MATERIALS & INTERFACES 2024; 16:21557-21570. [PMID: 38648555 DOI: 10.1021/acsami.4c00910] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 04/25/2024]
Abstract
We report the synthesis of biocompatible perfluorinated micelles designed to improve radiotherapeutic efficacy in a radioresistant tumor environment. In vitro and in vivo behaviors of perfluorinated micelles were assessed at both cellular and tissular levels. The micellar platform offers key advantages as theranostic tool: (i) small size, allowing deep tissue penetration; (ii) oxygen transport to hypoxic tissues; (iii) negligible toxicity in the absence of ionizing radiation; (iv) internalization into cancer cells; (v) potent radiosensitizing effect; and (vi) excellent tumor-targeting properties, as monitored by positron emission tomography. We have demonstrated strong in vitro radiosensitizing effects of the micelle and in vivo tumor targeting, making this nanometric carrier a promising tool for the potentiation of focused radiotherapy.
Collapse
Affiliation(s)
- Sophia Godel-Pastre
- Université Paris-Saclay, CEA, INRAE, Département Médicaments et Technologies pour la Santé (DMTS), SCBM, 91191 Gif-sur-Yvette, France
- Université Paris-Saclay, CEA, CNRS, Inserm, BioMaps, Service Hospitalier Frédéric Joliot, 4 place du Général Leclerc, 91401 Orsay, France
| | - Erika Porcel
- Université Paris-Saclay, CNRS,Institut des Sciences Moléculaires d'Orsay, 91401 Orsay, France
| | - Guillaume Pinna
- Plateforme ARN Interférence (PARI), Institut de Radiobiologie Cellulaire et Moléculaire (iRCM), Université Paris-Saclay, CEA, 92260 Fontenay-aux-Roses, France
| | - Marie Vandamme
- Plateforme ARN Interférence (PARI), Institut de Radiobiologie Cellulaire et Moléculaire (iRCM), Université Paris-Saclay, CEA, 92260 Fontenay-aux-Roses, France
| | - Caroline Denis
- Université Paris-Saclay, CEA, CNRS, Inserm, BioMaps, Service Hospitalier Frédéric Joliot, 4 place du Général Leclerc, 91401 Orsay, France
| | - Claire Leterrier
- Université Paris-Saclay, CEA, INRAE, Département Médicaments et Technologies pour la Santé (DMTS), SCBM, 91191 Gif-sur-Yvette, France
| | - Eric Doris
- Université Paris-Saclay, CEA, INRAE, Département Médicaments et Technologies pour la Santé (DMTS), SCBM, 91191 Gif-sur-Yvette, France
| | - Charles Truillet
- Université Paris-Saclay, CEA, CNRS, Inserm, BioMaps, Service Hospitalier Frédéric Joliot, 4 place du Général Leclerc, 91401 Orsay, France
| | - Edmond Gravel
- Université Paris-Saclay, CEA, INRAE, Département Médicaments et Technologies pour la Santé (DMTS), SCBM, 91191 Gif-sur-Yvette, France
| |
Collapse
|
2
|
Jamgotchian L, Devel L, Thai R, Poupel L, Huby T, Gautier E, Le Goff W, Lesnik P, Gravel E, Doris E. Targeted delivery of LXR-agonists to atherosclerotic lesions mediated by polydiacetylene micelles. NANOSCALE 2023; 15:18864-18870. [PMID: 37966726 DOI: 10.1039/d3nr04778d] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 11/16/2023]
Abstract
We report the development of compact and stabilized micelles incorporating a synthetic LXR agonist prodrug for the passive targeting of atherosclerotic lesions and therapeutic intervention. In vivo studies showed that the nanohybrid micelles exhibited favorable pharmacokinetics/biodistribution and were able to upregulate, to some extent, LXR target genes with no alteration of lipid metabolism.
Collapse
Affiliation(s)
- Lucie Jamgotchian
- Université Paris-Saclay, CEA, INRAE, Département Médicaments et Technologies pour la Santé (DMTS), SCBM, 91191 Gif-sur-Yvette, France.
| | - Laurent Devel
- Université Paris-Saclay, CEA, INRAE, Département Médicaments et Technologies pour la Santé (DMTS), SIMOS, 91191 Gif-sur-Yvette, France.
| | - Robert Thai
- Université Paris-Saclay, CEA, INRAE, Département Médicaments et Technologies pour la Santé (DMTS), SIMOS, 91191 Gif-sur-Yvette, France.
| | - Lucie Poupel
- Inovarion, 251 rue saint Jacques, 75005 Paris, France
| | - Thierry Huby
- Sorbonne Université, INSERM UMRS-1166, Institute of Cardiometabolism and Nutrition (ICAN), 75013 Paris, France.
| | - Emmanuel Gautier
- Sorbonne Université, INSERM UMRS-1166, Institute of Cardiometabolism and Nutrition (ICAN), 75013 Paris, France.
| | - Wilfried Le Goff
- Sorbonne Université, INSERM UMRS-1166, Institute of Cardiometabolism and Nutrition (ICAN), 75013 Paris, France.
| | - Philippe Lesnik
- Sorbonne Université, INSERM UMRS-1166, Institute of Cardiometabolism and Nutrition (ICAN), 75013 Paris, France.
| | - Edmond Gravel
- Université Paris-Saclay, CEA, INRAE, Département Médicaments et Technologies pour la Santé (DMTS), SCBM, 91191 Gif-sur-Yvette, France.
| | - Eric Doris
- Université Paris-Saclay, CEA, INRAE, Département Médicaments et Technologies pour la Santé (DMTS), SCBM, 91191 Gif-sur-Yvette, France.
| |
Collapse
|
3
|
Rabiei M, Kashanian S, Samavati SS, Derakhshankhah H, Jamasb S, McInnes SJP. Characteristics of SARS-CoV2 that may be useful for nanoparticle pulmonary drug delivery. J Drug Target 2021; 30:233-243. [PMID: 34415800 DOI: 10.1080/1061186x.2021.1971236] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/30/2022]
Abstract
As a non-invasive method of local and systemic drug delivery, the administration of active pharmaceutical ingredients (APIs) via the pulmonary route represents an ideal approach for the therapeutic treatment of pulmonary diseases. The pulmonary route provides a number of advantages, including the rapid absorption which results from a high level of vascularisation over a large surface area and the successful avoidance of first-pass metabolism. Aerosolization of nanoparticles (NPs) is presently under extensive investigation and exhibits a high potential for targeted delivery of therapeutic agents for the treatment of a wide range of diseases. NPs need to possess specific characteristics to facilitate their transport along the pulmonary tract and appropriately overcome the barriers presented by the pulmonary system. The most challenging aspect of delivering NP-based drugs via the pulmonary route is developing colloidal systems with the optimal physicochemical parameters for inhalation. The physiochemical properties of severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) have been investigated as a template for the synthesis of NPs to assist in the formulation of virus-like particles (VLPs) for pharmaceutical delivery, vaccine production and diagnosis assays.
Collapse
Affiliation(s)
- Morteza Rabiei
- Nanobiotechnology Department, Faculty of Innovative Science and Technology, Razi University, Kermanshah, Iran
| | - Soheila Kashanian
- Nanobiotechnology Department, Faculty of Innovative Science and Technology, Razi University, Kermanshah, Iran.,Faculty of Chemistry, Sensor and Biosensor Research Center (SBRC) and Nanoscience and Nanotechnology Research Center (NNRC), Razi University, Kermanshah, Iran.,Nano Drug Delivery Research Center, Kermanshah University of Medical Science, Kermanshah, Iran
| | - Seyedeh Sabereh Samavati
- Nanobiotechnology Department, Faculty of Innovative Science and Technology, Razi University, Kermanshah, Iran
| | - Hossein Derakhshankhah
- Pharmaceutical Sciences Research Center, Health Institute, Kermanshah University of Medical Sciences, Kermanshah, Iran
| | - Shahriar Jamasb
- Department of Biomedical Engineering, Hamedan University of Technology, Hamedan, Iran
| | - Steven J P McInnes
- University of South Australia, UniSA STEM, Mawson Lakes, South Australia
| |
Collapse
|
4
|
Minamisakamoto T, Nishiguchi S, Hashimoto K, Ogawara KI, Maruyama M, Higaki K. Sequential administration of PEG-Span 80 niosome enhances anti-tumor effect of doxorubicin-containing PEG liposome. Eur J Pharm Biopharm 2021; 169:20-28. [PMID: 34461216 DOI: 10.1016/j.ejpb.2021.08.013] [Citation(s) in RCA: 15] [Impact Index Per Article: 5.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/19/2021] [Revised: 08/16/2021] [Accepted: 08/23/2021] [Indexed: 10/20/2022]
Abstract
To improve the anti-tumor effect of polyethylene glycol-modified liposome containing doxorubicin (DOX-PEG liposome), the effect of sequential administration of PEG-Span 80 niosome was investigated for Colon-26 cancer cells (C26)-bearing mice. The concept of the current study is as follows: Since both particulates would be accumulated in the tumor tissue due to the enhanced permeability and retention (EPR) effect, PEG-Span 80 niosome, mainly composed of synthetic surfactant (Span 80), would interact with DOX-PEG liposome and be a trigger to induce the release of DOX from the liposome within the tumor tissue, leading to the improvement of anti-tumor effect of DOX-PEG liposome. To find out an adequate liposome for this strategy, several PEG liposomes with different compositions were examined in terms of drug release enhancement and it was found that PEG-Span80 niosome could significantly enhance the release of calcein and DOX from a PEG liposome composed of 90% hydrogenated soybean phosphatidylcholine (HSPC) and 10% cholesterol. The sequential administration of PEG-Span 80 niosome at 24 or 48 h after dosing of DOX-PEG liposome provided a higher anti-tumor effect than the single dose of DOX-PEG liposome in the C26-bearing mice. Particularly, the 24 h-later dosing of PEG-Span 80 niosome has been found to be more effective than the 48 h-later dosing. It was also confirmed that the coexistence of PEG-Span 80 niosome with DOX-PEG liposome in 50% serum or in 50% supernatant of tumor tissue homogenate significantly increased DOX release from PEG liposome, suggesting that DOX release from DOX-PEG liposome within tumor tissue would be enhanced via the interaction with PEG-Span 80 niosome. This strategy would lead to the safer and more inexpensive chemotherapy, since it could make it possible to provide the better anti-tumor effect by utilizing the lower dose of DOX.
Collapse
Affiliation(s)
- Takaya Minamisakamoto
- Department of Pharmaceutics, Faculty of Pharmaceutical Sciences, Okayama University, 1-1-1 Tsushima-naka, Kita-ku, Okayama 700-8530, Japan
| | - Shuhei Nishiguchi
- Department of Pharmaceutics, Faculty of Pharmaceutical Sciences, Okayama University, 1-1-1 Tsushima-naka, Kita-ku, Okayama 700-8530, Japan
| | - Kazuki Hashimoto
- Laboratory of Pharmaceutics, Kobe Pharmaceutical University, 4-19-1, Motoyamakita, Higashinada-ku, Kobe, Hyogo 658-8558, Japan
| | - Ken-Ichi Ogawara
- Laboratory of Pharmaceutics, Kobe Pharmaceutical University, 4-19-1, Motoyamakita, Higashinada-ku, Kobe, Hyogo 658-8558, Japan
| | - Masato Maruyama
- Department of Pharmaceutics, Faculty of Pharmaceutical Sciences, Okayama University, 1-1-1 Tsushima-naka, Kita-ku, Okayama 700-8530, Japan
| | - Kazutaka Higaki
- Department of Pharmaceutics, Faculty of Pharmaceutical Sciences, Okayama University, 1-1-1 Tsushima-naka, Kita-ku, Okayama 700-8530, Japan.
| |
Collapse
|
5
|
Jamgotchian L, Vaillant S, Selingue E, Doerflinger A, Belime A, Vandamme M, Pinna G, Ling WL, Gravel E, Mériaux S, Doris E. Tumor-targeted superfluorinated micellar probe for sensitive in vivo19F-MRI. NANOSCALE 2021; 13:2373-2377. [PMID: 33465227 DOI: 10.1039/d0nr08200g] [Citation(s) in RCA: 15] [Impact Index Per Article: 5.0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 06/12/2023]
Abstract
We describe herein the assembly and in vivo evaluation of a tailor-made micellar carrier system designed for the optimized encapsulation of a superfluorinated MRI probe and further targeting of solid tumors. The in vivo validation was carried out on MC38 tumor-bearing mice which allowed the confirmation of the efficient targeting properties of the nano-carrier, as monitored by 19F-MRI.
Collapse
Affiliation(s)
- Lucie Jamgotchian
- Université Paris-Saclay, CEA, INRAE, Département Médicaments et Technologies pour la Santé (DMTS), SCBM, 91191 Gif-sur-Yvette, France.
| | - Solenne Vaillant
- Université Paris-Saclay, CEA, CNRS, BAOBAB, NeuroSpin, 91191 Gif-sur-Yvette, France. and Sanofi Aventis Recherche Développement, 94400 Vitry-sur-Seine, France
| | - Erwan Selingue
- Université Paris-Saclay, CEA, CNRS, BAOBAB, NeuroSpin, 91191 Gif-sur-Yvette, France.
| | - Anaelle Doerflinger
- Université Paris-Saclay, CEA, INRAE, Département Médicaments et Technologies pour la Santé (DMTS), SCBM, 91191 Gif-sur-Yvette, France.
| | - Agathe Belime
- Université Paris-Saclay, CEA, INRAE, Département Médicaments et Technologies pour la Santé (DMTS), SCBM, 91191 Gif-sur-Yvette, France.
| | - Marie Vandamme
- Université Paris-Saclay, CEA, CNRS, Institute for Integrative Biology of the Cell (I2BC), 91198 Gif-sur-Yvette, France
| | - Guillaume Pinna
- Université Paris-Saclay, CEA, CNRS, Institute for Integrative Biology of the Cell (I2BC), 91198 Gif-sur-Yvette, France
| | - Wai Li Ling
- Université Grenoble Alpes, CEA, CNRS, IBS, 38000 Grenoble, France
| | - Edmond Gravel
- Université Paris-Saclay, CEA, INRAE, Département Médicaments et Technologies pour la Santé (DMTS), SCBM, 91191 Gif-sur-Yvette, France.
| | - Sébastien Mériaux
- Université Paris-Saclay, CEA, CNRS, BAOBAB, NeuroSpin, 91191 Gif-sur-Yvette, France.
| | - Eric Doris
- Université Paris-Saclay, CEA, INRAE, Département Médicaments et Technologies pour la Santé (DMTS), SCBM, 91191 Gif-sur-Yvette, France.
| |
Collapse
|
6
|
Osorno LL, Brandley AN, Maldonado DE, Yiantsos A, Mosley RJ, Byrne ME. Review of Contemporary Self-Assembled Systems for the Controlled Delivery of Therapeutics in Medicine. NANOMATERIALS (BASEL, SWITZERLAND) 2021; 11:278. [PMID: 33494400 PMCID: PMC7911285 DOI: 10.3390/nano11020278] [Citation(s) in RCA: 34] [Impact Index Per Article: 11.3] [Reference Citation Analysis] [Abstract] [Key Words] [Grants] [Track Full Text] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Received: 12/22/2020] [Revised: 01/12/2021] [Accepted: 01/15/2021] [Indexed: 12/12/2022]
Abstract
The novel and unique design of self-assembled micro and nanostructures can be tailored and controlled through the deep understanding of the self-assembly behavior of amphiphilic molecules. The most commonly known amphiphilic molecules are surfactants, phospholipids, and block copolymers. These molecules present a dual attraction in aqueous solutions that lead to the formation of structures like micelles, hydrogels, and liposomes. These structures can respond to external stimuli and can be further modified making them ideal for specific, targeted medical needs and localized drug delivery treatments. Biodegradability, biocompatibility, drug protection, drug bioavailability, and improved patient compliance are among the most important benefits of these self-assembled structures for drug delivery purposes. Furthermore, there are numerous FDA-approved biomaterials with self-assembling properties that can help shorten the approval pathway of efficient platforms, allowing them to reach the therapeutic market faster. This review focuses on providing a thorough description of the current use of self-assembled micelles, hydrogels, and vesicles (polymersomes/liposomes) for the extended and controlled release of therapeutics, with relevant medical applications. FDA-approved polymers, as well as clinically and commercially available nanoplatforms, are described throughout the paper.
Collapse
Affiliation(s)
| | | | | | | | | | - Mark E. Byrne
- Biomimetic & Biohybrid Materials, Biomedical Devices, & Drug Delivery Laboratories, Department of Biomedical Engineering, Rowan University, Glassboro, NJ 08028, USA
| |
Collapse
|
7
|
Nifant’ev I, Siniavin A, Karamov E, Kosarev M, Kovalchuk S, Turgiev A, Nametkin S, Bagrov V, Tavtorkin A, Ivchenko P. A New Approach to Developing Long-Acting Injectable Formulations of Anti-HIV Drugs: Poly(Ethylene Phosphoric Acid) Block Copolymers Increase the Efficiency of Tenofovir against HIV-1 in MT-4 Cells. Int J Mol Sci 2020; 22:ijms22010340. [PMID: 33396968 PMCID: PMC7795142 DOI: 10.3390/ijms22010340] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/02/2020] [Revised: 12/25/2020] [Accepted: 12/28/2020] [Indexed: 12/15/2022] Open
Abstract
Despite the world’s combined efforts, human immunodeficiency virus (HIV), the causative agent of AIDS, remains one of the world’s most serious public health challenges. High genetic variability of HIV complicates the development of anti-HIV vaccine, and there is an actual clinical need for increasing the efficiency of anti-HIV drugs in terms of targeted delivery and controlled release. Tenofovir (TFV), a nucleotide-analog reverse transcriptase inhibitor, has gained wide acceptance as a drug for pre-exposure prophylaxis or treatment of HIV infection. In our study, we explored the potential of tenofovir disoproxil (TFD) adducts with block copolymers of poly(ethylene glycol) monomethyl ether and poly(ethylene phosphoric acid) (mPEG-b-PEPA) as candidates for developing a long-acting/controlled-release formulation of TFV. Two types of mPEG-b-PEPA with numbers of ethylene phosphoric acid (EPA) fragments of 13 and 49 were synthesized by catalytic ring-opening polymerization, and used for preparing four types of adducts with TFD. Antiviral activity of [mPEG-b-PEPA]TFD or tenofovir disoproxil fumarate (TDF) was evaluated using the model of experimental HIV infection in vitro (MT-4/HIV-1IIIB). Judging by the values of the selectivity index (SI), TFD exhibited an up to 14-fold higher anti-HIV activity in the form of mPEG-b-PEPA adducts, thus demonstrating significant promise for further development of long-acting/controlled-release injectable TFV formulations.
Collapse
Affiliation(s)
- Ilya Nifant’ev
- Chemistry Department, M.V. Lomonosov Moscow State University, 1–3 Leninskie Gory, 119991 Moscow, Russia; (M.K.); (S.N.); (V.B.); (P.I.)
- A.V. Topchiev Institute of Petrochemical Synthesis RAS, 29 Leninsky Pr., 119991 Moscow, Russia;
- Faculty of Chemistry, National Research University Higher School of Economics, Miasnitskaya Str. 20, 101000 Moscow, Russia
- Correspondence: ; Tel.: +7-495-939-4098
| | - Andrei Siniavin
- N.F. Gamaleya National Research Center for Epidemiology and Microbiology MHRF, 18 Gamaleya Str., 123098 Moscow, Russia; (A.S.); (E.K.); (A.T.)
- Shemyakin-Ovchinnikov Institute of Bioorganic Chemistry, Russian Academy of Sciences, 117997 Moscow, Russia;
| | - Eduard Karamov
- N.F. Gamaleya National Research Center for Epidemiology and Microbiology MHRF, 18 Gamaleya Str., 123098 Moscow, Russia; (A.S.); (E.K.); (A.T.)
| | - Maxim Kosarev
- Chemistry Department, M.V. Lomonosov Moscow State University, 1–3 Leninskie Gory, 119991 Moscow, Russia; (M.K.); (S.N.); (V.B.); (P.I.)
| | - Sergey Kovalchuk
- Shemyakin-Ovchinnikov Institute of Bioorganic Chemistry, Russian Academy of Sciences, 117997 Moscow, Russia;
| | - Ali Turgiev
- N.F. Gamaleya National Research Center for Epidemiology and Microbiology MHRF, 18 Gamaleya Str., 123098 Moscow, Russia; (A.S.); (E.K.); (A.T.)
| | - Sergey Nametkin
- Chemistry Department, M.V. Lomonosov Moscow State University, 1–3 Leninskie Gory, 119991 Moscow, Russia; (M.K.); (S.N.); (V.B.); (P.I.)
| | - Vladimir Bagrov
- Chemistry Department, M.V. Lomonosov Moscow State University, 1–3 Leninskie Gory, 119991 Moscow, Russia; (M.K.); (S.N.); (V.B.); (P.I.)
| | - Alexander Tavtorkin
- A.V. Topchiev Institute of Petrochemical Synthesis RAS, 29 Leninsky Pr., 119991 Moscow, Russia;
| | - Pavel Ivchenko
- Chemistry Department, M.V. Lomonosov Moscow State University, 1–3 Leninskie Gory, 119991 Moscow, Russia; (M.K.); (S.N.); (V.B.); (P.I.)
- A.V. Topchiev Institute of Petrochemical Synthesis RAS, 29 Leninsky Pr., 119991 Moscow, Russia;
| |
Collapse
|
8
|
Kumar RA, Jawale DV, Oheix E, Geertsen V, Gravel E, Doris E. Tailor‐Made Polydiacetylene Micelles for the Catalysis of 1,3‐Dipolar Cycloadditions in Water. Adv Synth Catal 2020. [DOI: 10.1002/adsc.202000795] [Citation(s) in RCA: 10] [Impact Index Per Article: 2.5] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/02/2023]
Affiliation(s)
- Ramar Arun Kumar
- Université Paris-Saclay CEA, INRAE, Département Médicaments et Technologies pour la Santé (DMTS), SCBM 91191 Gif-sur-Yvette France 91
- SRM Research Institute Department of Chemistry SRM Institute of Science and Technology, Kattankulathur 603203 Chennai India
| | - Dhanaji V. Jawale
- Université Paris-Saclay CEA, INRAE, Département Médicaments et Technologies pour la Santé (DMTS), SCBM 91191 Gif-sur-Yvette France 91
| | - Emmanuel Oheix
- Université Paris-Saclay CEA, INRAE, Département Médicaments et Technologies pour la Santé (DMTS), SCBM 91191 Gif-sur-Yvette France 91
| | - Valérie Geertsen
- Université Paris-Saclay CEA, CNRS, NIMBE 91191 Gif-sur-Yvette France
| | - Edmond Gravel
- Université Paris-Saclay CEA, INRAE, Département Médicaments et Technologies pour la Santé (DMTS), SCBM 91191 Gif-sur-Yvette France 91
| | - Eric Doris
- Université Paris-Saclay CEA, INRAE, Département Médicaments et Technologies pour la Santé (DMTS), SCBM 91191 Gif-sur-Yvette France 91
| |
Collapse
|